| __timestamp | Arrowhead Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 34916000 |
| Thursday, January 1, 2015 | 34718089 | 36949000 |
| Friday, January 1, 2016 | 40998209 | 45240000 |
| Sunday, January 1, 2017 | 32022880 | 62416000 |
| Monday, January 1, 2018 | 19110051 | 81289000 |
| Tuesday, January 1, 2019 | 26556257 | 100359000 |
| Wednesday, January 1, 2020 | 52275890 | 105326000 |
| Friday, January 1, 2021 | 80981000 | 122356000 |
| Saturday, January 1, 2022 | 124431000 | 152848000 |
| Sunday, January 1, 2023 | 90932000 | 184259000 |
| Monday, January 1, 2024 | 98761000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Arrowhead Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Corcept's SG&A expenses have shown a remarkable upward trend, peaking in 2023 with a 428% increase from 2014. In contrast, Arrowhead's expenses have also grown, but at a steadier pace, with a 304% rise over the same period. Notably, Corcept's expenses surpassed Arrowhead's consistently from 2017 onwards, highlighting a more aggressive investment in administrative and sales functions. However, data for 2024 is incomplete, leaving room for speculation on future trends. This financial insight provides a window into the strategic priorities of these biotech giants, reflecting their commitment to growth and market expansion.
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
BeiGene, Ltd. or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Genmab A/S and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation